Recall Register

Drug recall: Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net content 6.7 g canister packaged in a box, Rx…

Class I FDA enforcement event 92616. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Class I, in the words of FDA

a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death

Cipla USA, Inc. started this drug recall on 27 Jun 2023. The firm address in the FDA record is in Warren, NJ. FDA put the recall in Class I. FDA event 92616 has 1 product record. The first FDA enforcement report date is 19 Jul 2023. The record gives the status Terminated, with the termination date 6 Mar 2025.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the US

Recalling firm

Cipla USA, Inc., Warren, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 92616: product records
Recall numberProductQuantityClassStatusReport date
D-0938-2023Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net content 6.7 g canister packaged in a box, Rx only, Manufactured by: Cipla Ltd, Indore SE Z, Pithampur, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ, 07059, NDC 69097-142-60278,538 canistersClass ITerminated19 Jul 2023

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class I: The highest of the three FDA recall classes.

The event in context

Drug events that started in 2023
281
Share of these events in Class I
15%
Product records in this event
1Median of the firm: 2
Events of the firm on the register
13

Other events of the firm

Other FDA enforcement events of Cipla USA, Inc.
InitiatedProduct (first record)TypeClassRecords
29 Jun 2026Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India;DrugClass II3
16 Mar 2026Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, DrugClass II3
13 Mar 2026Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle, Single dose only, Rx Only, DrugClass II2
18 Feb 2026Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, MaDrugClass III2
2 Jan 2026Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, ManufacturDrugClass II1
22 Dec 2025Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine StreDrugClass III1
14 Nov 2025Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 IndependeDrugClass II3
24 Oct 2025Lanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack carton, Rx Only, Manufactured by: Invagen PDrugClass II2
24 Jul 2025Albuterol Sulfate, Inhalation Aerosol, 90 mcg, 200 metered Inhalations, NET CONTENT 6.7 g, Manufactured by: Cipla Ltd, IDrugClass III1
30 Jun 2025Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured byDrugClass II1

Cipla USA, Inc.: all 13 events

Official channels

Cite this page

Recall Register. FDA enforcement event 92616. https://recallregister.com/fda/i/92616/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the US
What quantity of product is in FDA event 92616?
The FDA record gives this quantity: 278,538 canisters
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2023 have the same class?
15% of the 281 drug events that started in 2023 are in Class I.